<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540380</url>
  </required_header>
  <id_info>
    <org_study_id>Tolerance SMC-MGH</org_study_id>
    <nct_id>NCT04540380</nct_id>
  </id_info>
  <brief_title>Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH</brief_title>
  <official_title>Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to investigate the safety of the conditioning regimen, and its ability to induce&#xD;
      donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS),&#xD;
      which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the&#xD;
      absence of maintenance immunosuppression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Transient Chimerism</measure>
    <time_frame>36 months after immunosuppression withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Chimerism Transition Syndrome</measure>
    <time_frame>36 months after immunosuppression withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of tolerance induction</measure>
    <time_frame>36 months after immunosuppression withdrawal</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Renal Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab</intervention_name>
    <description>Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined bone marrow and kidney transplant</intervention_name>
    <description>Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-60 years of age.&#xD;
&#xD;
          -  Candidate for a living-donor renal allograft from an HLA mismatched donor&#xD;
&#xD;
          -  Subjects with chronic kidney disease stage or ESRD who are treated with either&#xD;
             hemodialysis or peritoneal dialysis.&#xD;
&#xD;
          -  First transplant.&#xD;
&#xD;
          -  Use of FDA-approved methods of contraception&#xD;
&#xD;
          -  Ability to understand and provide informed consent.&#xD;
&#xD;
          -  Serologic evidence of prior exposure to EBV&#xD;
&#xD;
          -  Negative COVID at screening and 2 days before procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ABO blood group-incompatible renal allograft.&#xD;
&#xD;
          -  Evidence of anti-HLA antibody (donor specific or not) within 60 days prior to&#xD;
             transplant as assessed by routine methodology (Luminex)&#xD;
&#xD;
          -  Persistent Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (&lt;100,000/mm3).&#xD;
&#xD;
          -  Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (confirmed by&#xD;
             hepatitis C virus RNA); or positivity for hepatitis B surface antigen.&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40% as determined by TTE or clinical evidence of&#xD;
             heart failure&#xD;
&#xD;
          -  Forced expiratory volume FEV1 or DLCO &lt; 50% of predicted.&#xD;
&#xD;
          -  Lactation or pregnancy&#xD;
&#xD;
          -  History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  Underlying renal disease etiology with a high risk of disease recurrence in the&#xD;
             transplanted kidney (such as focal segmental glomerulosclerosis).&#xD;
&#xD;
          -  Prior dose-limiting radiation therapy&#xD;
&#xD;
          -  Known genetic disease or family history that may result in greater sensitivity to the&#xD;
             effects of irradiation, or a physical deformity that would preclude adequate shielding&#xD;
             or appropriate dosing during the irradiation component of the conditioning regimen&#xD;
&#xD;
          -  Enrollment in other investigational drug studies within 30 days prior to enrollment&#xD;
&#xD;
          -  Abnormal (&gt;2 times lab normal) values for (a) liver function chemistries (ALT, AST,&#xD;
             AP), (b) bilirubin, (c) coagulation studies (PT, PTT).&#xD;
&#xD;
          -  Allergy or sensitivity to any component of Siplizumab, Fludarabine, Cyclophosphamide&#xD;
             tacrolimus, MMF or rituximab&#xD;
&#xD;
          -  The presence of any medical condition that the investigator deems incompatible with&#xD;
             participation in the trial.&#xD;
&#xD;
          -  Subjects who have non-insulin dependent diabetes (NIDDM) without good blood glucose&#xD;
             control (HbA1c&lt;7). Subject with severe retinopathy, gastroparesis, or severe&#xD;
             neuropathy which prevent subject's normal independent daily activities will be&#xD;
             excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatsuo Kawai, MD PhD</last_name>
    <phone>617-726-0289</phone>
    <email>tkawai@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabe Impreso Baysa, BS</last_name>
    <phone>617-643-7569</phone>
    <email>gimpresobaysa@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tatsuo Kawai, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

